Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2018

Open Access 01-12-2018 | Research article

Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study

Authors: Nele Laleman, Séverine Henrard, Marjan van den Akker, Geert Goderis, Frank Buntinx, Gijs Van Pottelbergh, Bert Vaes

Published in: BMC Cardiovascular Disorders | Issue 1/2018

Login to get access

Abstract

Background

The current study evaluated time trends of statin use and incidence of recurrent CVD in secondary prevention from 1999 to 2013 and investigated which factors were associated with statin use in secondary prevention.

Methods

Intego is a primary care registration network with 111 general practitioners working in 48 practices in Flanders, Belgium. This retrospective registry-based study included patients aged 50 years or older with a history of CVD. The time trends of statin use and incidence of recurrent CVD in secondary prevention were determined by using a joinpoint regression analysis. Multivariable mixed-effect logistic regression analysis was used to assess factors associated with statin use in patients in secondary prevention in 2013.

Results

The overall prevalence of statin use increased and showed two trends: a sharp increase from 1999 to 2005 (annual percentage change (APC) 25.4%) and a weaker increase from 2005 to 2013 (APC 3.7%). The average increase in statin use was the highest in patients aged 80 and older. Patients aged 70–79 years received the most statins. Men used more statins than women did, but both genders showed similar time trends. The incidence of CVD decreased by an average APC of 3.9%. There were no differences between men and women and between different age groups. A significant decrease was only observed in older patients without statins prescribed. In 2013, 61% of the patients in secondary prevention did not receive a statin. The absence of other secondary preventive medication was strongly associated with less statin use. Gender, age and comorbidity were associated with statin use to a lesser degree.

Conclusions

The prevalence of statin use in secondary prevention increased strongly from 1999 to 2013. Less than 50% of patients with a history of CVD received a statin in 2013. Especially patients who did not receive other secondary preventive medication were more likely to not receive a statin. Despite the strong increase in statin use, there was only a small decrease in the incidence of recurrent CVD, and this occurred mainly in older patients without statins prescribed.
Literature
2.
go back to reference Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol. 2015;201 Suppl 1:S1–7.CrossRef Bansilal S, Castellano JM, Fuster V. Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol. 2015;201 Suppl 1:S1–7.CrossRef
3.
go back to reference De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10:S1–S10.PubMed De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2003;10:S1–S10.PubMed
4.
go back to reference Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–934.CrossRef Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–934.CrossRef
5.
go back to reference Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:E1–40.CrossRef Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:E1–40.CrossRef
6.
go back to reference Ong HT. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM. 2005;98:599–614.CrossRef Ong HT. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM. 2005;98:599–614.CrossRef
7.
go back to reference Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9. Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.
8.
go back to reference Descamps OS, De Backer G, Annemans L, Muls E, Scheen AJ. New European guidelines for the management of dyslipidaemia in cardiovascular prevention. Rev Med Liege. 2012;67:118–27.PubMed Descamps OS, De Backer G, Annemans L, Muls E, Scheen AJ. New European guidelines for the management of dyslipidaemia in cardiovascular prevention. Rev Med Liege. 2012;67:118–27.PubMed
9.
go back to reference Dodhia H, Kun L, Logan Ellis H, Crompton J, Wierzbicki AS, Williams H, et al. Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London borough. BMJ Open. 2015;5:e008678.CrossRef Dodhia H, Kun L, Logan Ellis H, Crompton J, Wierzbicki AS, Williams H, et al. Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London borough. BMJ Open. 2015;5:e008678.CrossRef
10.
go back to reference Wallach Kildemoes H, Vass M, Hendriksen C, Andersen M. Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy. 2012;108:216–27.CrossRef Wallach Kildemoes H, Vass M, Hendriksen C, Andersen M. Statin utilization according to indication and age: a Danish cohort study on changing prescribing and purchasing behaviour. Health Policy. 2012;108:216–27.CrossRef
11.
go back to reference Bejot Y, Zeller M, Lorgis L, Troisgros O, Aboa-Eboule C, Osseby GV, et al. Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications. J Neurol Neurosurg Psychiatry. 2013;84:348–53.CrossRef Bejot Y, Zeller M, Lorgis L, Troisgros O, Aboa-Eboule C, Osseby GV, et al. Secondary prevention in patients with vascular disease. A population based study on the underuse of recommended medications. J Neurol Neurosurg Psychiatry. 2013;84:348–53.CrossRef
12.
go back to reference Jorgensen CH, Gislason GH, Ahlehoff O, Andersson C, Torp-Pedersen C, Hansen PR. Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus. BMC Cardiovasc Disord. 2014;14:4.CrossRef Jorgensen CH, Gislason GH, Ahlehoff O, Andersson C, Torp-Pedersen C, Hansen PR. Use of secondary prevention pharmacotherapy after first myocardial infarction in patients with diabetes mellitus. BMC Cardiovasc Disord. 2014;14:4.CrossRef
13.
go back to reference Park JH, Ruiz MC, Shields D, Orr DJ. Socioeconomic deprivation does not affect prescribing of secondary prevention in patients with peripheral arterial disease. Int Angiol. 2013;32:593–8.PubMed Park JH, Ruiz MC, Shields D, Orr DJ. Socioeconomic deprivation does not affect prescribing of secondary prevention in patients with peripheral arterial disease. Int Angiol. 2013;32:593–8.PubMed
15.
go back to reference DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart. 2003;89:417–21.CrossRef DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart. 2003;89:417–21.CrossRef
16.
go back to reference Subherwal S, Patel MR, Kober L, Peterson ED, Jones WS, Gislason GH, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012;126:1345–54.CrossRef Subherwal S, Patel MR, Kober L, Peterson ED, Jones WS, Gislason GH, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012;126:1345–54.CrossRef
17.
go back to reference Fitzgerald TN, Popp C, Dardik A, Federman DG. Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy. Vasc Med. 2009;14:21–7.CrossRef Fitzgerald TN, Popp C, Dardik A, Federman DG. Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy. Vasc Med. 2009;14:21–7.CrossRef
18.
go back to reference Tu JV, Gong Y. Trends in treatment and outcomes for acute stroke patients in Ontario, 1992-1998. Arch Intern Med. 2003;163:293–7.CrossRef Tu JV, Gong Y. Trends in treatment and outcomes for acute stroke patients in Ontario, 1992-1998. Arch Intern Med. 2003;163:293–7.CrossRef
19.
go back to reference Ovbiagele B, Schwamm LH, Smith EE, Hernandez AF, Olson DM, Pan W, et al. Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke. 2010;41:1508–13.CrossRef Ovbiagele B, Schwamm LH, Smith EE, Hernandez AF, Olson DM, Pan W, et al. Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke. 2010;41:1508–13.CrossRef
20.
go back to reference Lemaitre RN, Furberg CD, Newman AB, Hulley SB, Gordon DJ, Gottdiener JS, et al. Time trends in the use of cholesterol-lowering agents in older adults: the cardiovascular health study. Arch Intern Med. 1998;158:1761–8.CrossRef Lemaitre RN, Furberg CD, Newman AB, Hulley SB, Gordon DJ, Gottdiener JS, et al. Time trends in the use of cholesterol-lowering agents in older adults: the cardiovascular health study. Arch Intern Med. 1998;158:1761–8.CrossRef
21.
go back to reference Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart. 2002;88:25–9.CrossRef Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart. 2002;88:25–9.CrossRef
22.
go back to reference Young F, Capewell S, Ford ES, Critchley JA. Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention. Am J Prev Med. 2010;39:228–34.CrossRef Young F, Capewell S, Ford ES, Critchley JA. Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention. Am J Prev Med. 2010;39:228–34.CrossRef
23.
go back to reference Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo health study 2000-2001. J Intern Med. 2004;255:494–502.CrossRef Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo health study 2000-2001. J Intern Med. 2004;255:494–502.CrossRef
24.
go back to reference Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P, et al. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol. 2007;63:197–203.CrossRef Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P, et al. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol. 2007;63:197–203.CrossRef
25.
go back to reference Li X, Gao Y, Li J, Feng F, Liu JM, Zhang HB, et al. Underuse of statins in patients with atherosclerotic ischemic stroke in China. Chin Med J (Engl). 2012;125:1703–7. Li X, Gao Y, Li J, Feng F, Liu JM, Zhang HB, et al. Underuse of statins in patients with atherosclerotic ischemic stroke in China. Chin Med J (Engl). 2012;125:1703–7.
26.
go back to reference Di Martino M, Degli Esposti L, Ruffo P, Bustacchini S, Catte A, Sturani A, et al. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol. 2005;61:225–30.CrossRef Di Martino M, Degli Esposti L, Ruffo P, Bustacchini S, Catte A, Sturani A, et al. Underuse of lipid-lowering drugs and factors associated with poor adherence: a real practice analysis in Italy. Eur J Clin Pharmacol. 2005;61:225–30.CrossRef
27.
go back to reference Shalev V, Weil C, Raz R, Goldshtein I, Weitzman D, Chodick G. Trends in statin therapy initiation during the period 2000-2010 in Israel. Eur J Clin Pharmacol. 2014;70:557–64.CrossRef Shalev V, Weil C, Raz R, Goldshtein I, Weitzman D, Chodick G. Trends in statin therapy initiation during the period 2000-2010 in Israel. Eur J Clin Pharmacol. 2014;70:557–64.CrossRef
28.
go back to reference Girot M, Mackowiak-Cordoliani MA, Deplanque D, Henon H, Lucas C, Leys D. Secondary prevention after ischemic stroke. Evolution over time in practice. J Neurol. 2005;252:14–20.CrossRef Girot M, Mackowiak-Cordoliani MA, Deplanque D, Henon H, Lucas C, Leys D. Secondary prevention after ischemic stroke. Evolution over time in practice. J Neurol. 2005;252:14–20.CrossRef
29.
go back to reference Balder JW, Scholtens S, de Vries JK, van Schie LM, Boekholdt SM, Hovingh GK, et al. Adherence to guidelines to prevent cardiovascular diseases: the LifeLines cohort study. Neth J Med. 2015;73:316–23.PubMed Balder JW, Scholtens S, de Vries JK, van Schie LM, Boekholdt SM, Hovingh GK, et al. Adherence to guidelines to prevent cardiovascular diseases: the LifeLines cohort study. Neth J Med. 2015;73:316–23.PubMed
30.
go back to reference Sheppard JP, Fletcher K, McManus RJ, Mant J. Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study. Br J Gen Pract. 2014;64:e38–46.CrossRef Sheppard JP, Fletcher K, McManus RJ, Mant J. Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study. Br J Gen Pract. 2014;64:e38–46.CrossRef
32.
go back to reference Wallach-Kildemoes H, Stovring H, Holme Hansen E, Howse K, Petursson H. Statin prescribing according to gender, age and indication: what about the benefit-risk balance? J Eval Clin Pract. 2016;22:235–46.CrossRef Wallach-Kildemoes H, Stovring H, Holme Hansen E, Howse K, Petursson H. Statin prescribing according to gender, age and indication: what about the benefit-risk balance? J Eval Clin Pract. 2016;22:235–46.CrossRef
33.
go back to reference Rasmussen JN, Gislason GH, Abildstrom SZ, Rasmussen S, Gustafsson I, Buch P, et al. Statin use after acute myocardial infarction: a nationwide study in Denmark. Br J Clin Pharmacol. 2005;60:150–8.CrossRef Rasmussen JN, Gislason GH, Abildstrom SZ, Rasmussen S, Gustafsson I, Buch P, et al. Statin use after acute myocardial infarction: a nationwide study in Denmark. Br J Clin Pharmacol. 2005;60:150–8.CrossRef
34.
go back to reference Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL. Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Women's Health (Larchmt). 2008;17:515–21.CrossRef Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL. Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Women's Health (Larchmt). 2008;17:515–21.CrossRef
35.
go back to reference Mohammed MA, El Sayed C, Marshall T. Patient and other factors influencing the prescribing of cardiovascular prevention therapy in the general practice setting with and without nurse assessment. Med Decis Mak. 2012;32:498–506.CrossRef Mohammed MA, El Sayed C, Marshall T. Patient and other factors influencing the prescribing of cardiovascular prevention therapy in the general practice setting with and without nurse assessment. Med Decis Mak. 2012;32:498–506.CrossRef
36.
go back to reference Kildemoes HW, Stovring H, Andersen M. Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model. Br J Clin Pharmacol. 2008;66:885–95.CrossRef Kildemoes HW, Stovring H, Andersen M. Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model. Br J Clin Pharmacol. 2008;66:885–95.CrossRef
37.
go back to reference Truyers C, Goderis G, Dewitte H, Akker M, Buntinx F. The Intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project. BMC Med Inform Decis Mak. 2014;14:48.CrossRef Truyers C, Goderis G, Dewitte H, Akker M, Buntinx F. The Intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project. BMC Med Inform Decis Mak. 2014;14:48.CrossRef
38.
go back to reference Vaes B, Beke E, Truyers C, Elli S, Buntinx F, Verbakel JY, et al. The correlation between blood pressure and kidney function decline in older people: a registry-based cohort study. BMJ Open. 2015;5:e007571.CrossRef Vaes B, Beke E, Truyers C, Elli S, Buntinx F, Verbakel JY, et al. The correlation between blood pressure and kidney function decline in older people: a registry-based cohort study. BMJ Open. 2015;5:e007571.CrossRef
39.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.CrossRef
40.
go back to reference Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335–51.CrossRef Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335–51.CrossRef
41.
go back to reference Dean CB, Nielsen JD. Generalized linear mixed models: a review and some extensions. Lifetime Data Anal. 2007;13:497–512.CrossRef Dean CB, Nielsen JD. Generalized linear mixed models: a review and some extensions. Lifetime Data Anal. 2007;13:497–512.CrossRef
42.
go back to reference de Ruijter W, de Waal MW, Gussekloo J, Assendelft WJ, Blom JW. Time trends in preventive drug treatment after myocardial infarction in older patients. Br J Gen Pract. 2010;60:47–9.CrossRef de Ruijter W, de Waal MW, Gussekloo J, Assendelft WJ, Blom JW. Time trends in preventive drug treatment after myocardial infarction in older patients. Br J Gen Pract. 2010;60:47–9.CrossRef
43.
go back to reference Appelros P, Jonsson F, Asberg S, Asplund K, Glader EL, Asberg KH, et al. Trends in stroke treatment and outcome between 1995 and 2010: observations from Riks-stroke, the Swedish stroke register. Cerebrovasc Dis. 2014;37:22–9.CrossRef Appelros P, Jonsson F, Asberg S, Asplund K, Glader EL, Asberg KH, et al. Trends in stroke treatment and outcome between 1995 and 2010: observations from Riks-stroke, the Swedish stroke register. Cerebrovasc Dis. 2014;37:22–9.CrossRef
44.
go back to reference Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864–70.CrossRef Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291:1864–70.CrossRef
45.
go back to reference Fraeyman J, Van Hal G, De Loof H, Remmen R, De Meyer GR, Beutels P. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium. Acta Clin Belg. 2012;67:160–71.PubMed Fraeyman J, Van Hal G, De Loof H, Remmen R, De Meyer GR, Beutels P. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium. Acta Clin Belg. 2012;67:160–71.PubMed
47.
go back to reference Steinberg BA, Bhatt DL, Mehta S, Poole-Wilson PA, O'Hagan P, Montalescot G, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008;156:719–27.CrossRef Steinberg BA, Bhatt DL, Mehta S, Poole-Wilson PA, O'Hagan P, Montalescot G, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J. 2008;156:719–27.CrossRef
48.
go back to reference Wong ND, Patao C, Wong K, Malik S, Franklin SS, Iloeje U. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status. Diab Vasc Dis Res. 2013;10:505–13.CrossRef Wong ND, Patao C, Wong K, Malik S, Franklin SS, Iloeje U. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status. Diab Vasc Dis Res. 2013;10:505–13.CrossRef
49.
go back to reference Tang L, Patao C, Chuang J, Wong ND. Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and nutrition examination survey 2007-2010). Am J Cardiol. 2013;112:1126–32.CrossRef Tang L, Patao C, Chuang J, Wong ND. Cardiovascular risk factor control and adherence to recommended lifestyle and medical therapies in persons with coronary heart disease (from the National Health and nutrition examination survey 2007-2010). Am J Cardiol. 2013;112:1126–32.CrossRef
50.
go back to reference Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373–418.CrossRef Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8:373–418.CrossRef
51.
go back to reference Guttierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172:909–19.CrossRef Guttierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172:909–19.CrossRef
52.
go back to reference Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–30.CrossRef Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–30.CrossRef
53.
go back to reference Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350:1119–23.CrossRef Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk of mortality in the oldest old. Lancet. 1997;350:1119–23.CrossRef
54.
go back to reference Ho JE, Paultre F, Mosca L. Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's pooling project. Stroke. 2003;34:2812–6.CrossRef Ho JE, Paultre F, Mosca L. Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the Women's pooling project. Stroke. 2003;34:2812–6.CrossRef
55.
go back to reference Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.CrossRef Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.CrossRef
56.
go back to reference Golomb BA, Koperski S, White HL. Statins raise glucose preferentially among men who are older and at greater metabolic risk. Circulation. 2012;125:A055. Golomb BA, Koperski S, White HL. Statins raise glucose preferentially among men who are older and at greater metabolic risk. Circulation. 2012;125:A055.
57.
go back to reference Davidson W, Molloy DW, Bédard M. Physician characteristics and prescribing for elderly people in New Brunswick: relation to patient outcomes. CMAJ. 1995;152:1227–34.PubMedPubMedCentral Davidson W, Molloy DW, Bédard M. Physician characteristics and prescribing for elderly people in New Brunswick: relation to patient outcomes. CMAJ. 1995;152:1227–34.PubMedPubMedCentral
58.
go back to reference ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholseterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007.CrossRef ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholseterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA. 2002;288:2998–3007.CrossRef
59.
go back to reference Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29:800–11.CrossRef Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29:800–11.CrossRef
60.
go back to reference Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The effect of HMG-CoAreductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother. 2012;10:296–302.CrossRef Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The effect of HMG-CoAreductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother. 2012;10:296–302.CrossRef
61.
go back to reference Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004;94:1306–10.CrossRef Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004;94:1306–10.CrossRef
62.
go back to reference Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59.CrossRef Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59.CrossRef
63.
go back to reference Kjekhus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61.CrossRef Kjekhus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61.CrossRef
Metadata
Title
Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study
Authors
Nele Laleman
Séverine Henrard
Marjan van den Akker
Geert Goderis
Frank Buntinx
Gijs Van Pottelbergh
Bert Vaes
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2018
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0941-y

Other articles of this Issue 1/2018

BMC Cardiovascular Disorders 1/2018 Go to the issue